Pfizer's second-quarter results were better than expected. The drugmaker will still face some near-term uncertainty. However, its long-term prospects look attractive, especially at current levels. 10 ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Counterfeit Medicine is a growing global threat. At Pfizer, a dedicated team is leading the fight to stop these dangerous ...

Several workers at the Pfizer facility in Portage were taken to the hospital after the company said they may have been "exposed to materials" over the weekend.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...